🇺🇸 FDA
Company

Denali

Denali Therapeutics

DNLI biotech USA

Quick answer

Denali is a biotech company (DNLI) headquartered in SOUTH SAN FRANCISCO, CA, USA with 18 tracked pipeline programs.

Pipeline (18)

project

BIIB122

Parkinson Disease

Phase 3 · small_molecule · active

2 trials project

DNL343

Amyotrophic Lateral Sclerosis

Phase 3 · small_molecule · completed

2 trials project

tividenofusp alfa

Mucopolysaccharidosis II

Phase 3 · small_molecule · active

3 trials project

BIIB122 225 mg

Parkinson Disease

Phase 2 · small_molecule · active

1 trials project

DNL126

Mucopolysaccharidosis Type IIIA

Phase 2 · small_molecule · active

1 trials project

DNL593

Frontotemporal Dementia

Phase 2 · small_molecule · active

1 trials project

BIIB122 (DNL151)

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

DNL151

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

DNL201

Parkinson Disease

Phase 1 · small_molecule · completed

1 trials project

DNL201

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

DNL343

Healthy Volunteers

Phase 1 · small_molecule · completed

2 trials project

DNL628

Alzheimer Disease, Early Onset

Phase 1 · small_molecule · active

1 trials project

DNL747

Alzheimer Disease

Phase 1 · small_molecule · completed

1 trials project

DNL747

Amyotrophic Lateral Sclerosis

Phase 1 · small_molecule · terminated

1 trials project

DNL919

Healthy Participant

Phase 1 · small_molecule · completed

1 trials project

DNL952

Late-onset Pompe Disease

Phase 1 · small_molecule · active

1 trials project

[14C] BIIB122 ([14C] DNL151)

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

[14C]-DNL343

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

tividenofusp alfa-eknm

AVLAYAH

Patents (8)

patent

US 12378540

Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12358896

LRRK2 inhibitors and methods of making and using thereof

Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12358928

Compounds, compositions and methods

Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12240902

Anti-TREM2 antibodies and methods of use thereof

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12180211

Compounds, compositions and methods

Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12162948

Methods of engineering transferrin receptor binding polypeptides

Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12129263

Kinase inhibitors and uses thereof

Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11999750

Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)